

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/680,723
				Filing Date	October 7, 2003
				Confirmation Number	2648
				First Named Inventor	Michael S. South, et al.
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	1	of	6	Attorney Docket No.	PHA 4159.33 (3203/1B/US)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
M	1	4,489,096	B1	Terao et al.	12-18-1984
M	2	4,851,413	B1	Terao et al.	07-25-1989
M	3	4,992,469	B1	Ozawa et al.	02-12-1991
M	4	5,008,267		Katakami, et al.	04-16-1991
M	5	5,304,658	B1	Terao et al.	04-19-1994
M	6	5,441,960		Bernstein et al.	08-15-1995
M	7	5,656,645		Tamura et al.	08-12-1997
M	8	5,658,930		Tamura et al.	08-19-1997
M	9	5,668,289	B1	Sanderson et al.	09-16-1997
M	10	5,741,819	B1	Illig et al.	04-12-1998
M	11	5,792,779	B1	Sanderson et al.	08-11-1998
M	12	5,861,380	B1	Gyorkos et al.	01-19-1999
M	13	5,866,573	B1	Sanderson et al.	02-02-1999
M	14	5,869,487	B1	Coburn et al.	02-09-1999
M	15	5,872,138	B1	Naylor-Olsen et al.	02-16-1999

Examiner Signature	V. Bulavskiy	Date Considered	11/29/04
-----------------------	--------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/680,723
				Filing Date	October 7, 2003
				Confirmation Number	2648
				First Named Inventor	Michael S. South, et al.
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	2	of	6	Attorney Docket No.	PHA 4159.33 (3203/1B/US)

W	16	6,011,158	B1	Tamura et al.	01-04-2000
W	17	6,037,356	B1	Lu et al.	03-14-2000
W	18	6,180,627	B1	Blagg et al.	01-30-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
W	19	DE	198 51 421	A1	Boehringer Ingelheim Pharma KG	05-11-2000	
W	20	EP	0 354 495	A1	Godecke Aktiengesellschaft	02-14-1990	
W	21	EP	528 633	B1	Zeneca Limited	10-18-2000	
W	22	EP	826 671	A1	The Green Cross Corporation	03-04-1998	
W	23	EP	936 216	A1	Nippon Kayaku Kabushiki Kaisha	08-18-1999	
W	24	EP	940 400	A1	Yoshitomi Pharmaceutical Industries, Ltd.	09-08-1999	
W	25	EP	997 474	A1	Pfizer Inc.	05-03-2000	
W	26	WO	93/21214	A1	Zeneca Limited	10-28-1993	
W	27	WO	96/18644	A1	Corvas International Inc.	06-20-1996	
W	28	WO	96/33974	A1	The Green Cross Corporation (abstract)	10-31-1996	

Examiner Signature	V. Balasubramanian	Date Considered	11/29/04
-----------------------	--------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/680,723
				Filing Date	October 7, 2003
				Confirmation Number	2648
				First Named Inventor	Michael S. South, et al.
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	3	of	6	Attorney Docket No.	PHA 4159.33 (3203/1B/US)

M	29	WO	96/39380	A1	3-Dimensional Pharmaceuticals, Inc.	12-12-1996	
M	30	WO	96/40100	A1	3-Dimensional Pharmaceuticals, Inc.	12-19-1996	
M	31	WO	97/01338	A1	Merck & Co., Inc.	01-16-1997	
M	32	WO	97/30708	A1	Merck & Co., Inc.	08-28-1997	
M	33	WO	97/40024	A1	Merck & Co., Inc.	10-30-1997	
M	34	WO	97/46207	A2	Corvas International Inc.	12-11-1997	
M	35	WO	98/08840	A1	Merck & Co., Inc.	03-05-1998	
M	36	WO	98/09949	A1	Nippon KayKabushiki Kaisha (abstract)	03-12-1998	
M	37	WO	98/09987	A1	Biochem Pharma, Inc.	03-12-1998	
M	38	WO	98/10763	A1	Merck & Co., Inc.	03-19-1998	
M	39	WO	98/16525	A1	Cor Therapeutics, Inc.	04-23-1998	
M	40	WO	98/16547	A1	Cor Therapeutics, Inc.	04-23-1998	
M	41	WO	98/17274	A1	Merck & Co., Inc.	04-30-1998	
M	42	WO	98/31670	A1	Merck & Co., Inc.	07-23-1998	
M	43	WO	98/42342	A1	Merck & Co., Inc.	10-01-1998	
M	44	WO	98/47876	A1	Akzo Nobel N.V.	10-29-1998	
M	45	WO	98/50420	A1	Akzo Nobel N.V.	11-12-1998	
M	46	WO	99/00121	A1	Eli Lilly and Company	01-07-1999	

Examiner Signature	V. Dulasanbann	Date Considered	11/29/04
--------------------	----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/680,723
				Filing Date	October 7, 2003
				Confirmation Number	2648
				First Named Inventor	Michael S. South, et al.
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	4	of	6	Attorney Docket No.	PHA 4159.33 (3203/1B/US)

W	47	WO	99/00126	A1	Eli Lilly and Company	01-07-1999	
W	48	WO	99/00128	A1	Eli Lilly and Company	01-07-1999	
W	49	WO	99/11267	A1	Merck & Co., Inc.	03-11-1999	
W	50	WO	99/26920	A1	Corvas International, Inc.	06-03-1999	
W	51	WO	99/26926	A1	3-Dimensional Pharmaceuticals, Inc.	06-03-1999	
W	52	WO	99/36426	A1	Warner-Lambert Company	07-22-1999	
W	53	WO	99/43660	A1	Neurogen Corporation	09-02-1999	
W	54	WO	99/48892	A1	Merck & Sharp & Dohme Limited	09-30-1999	
W	55	WO	99/59591	A1	Merck & Co., Inc.	11-25-1999	
W	56	WO	99/61442	A1	Merck & Co., Inc.	12-02-1999	
W	57	WO	99/62538	A1	Warner-Lambert Company	07-22-1999	
W	58	WO	99/64446	A1	3-Dimensional Pharmaceuticals, Inc.	12-16-1999	
W	59	WO	00/18762	A1	Merck & Co., Inc.	04-06-2000	
W	60	WO	00/26210	A1	Merck & Co., Inc.	05-11-2000	
W	61	WO	00/26211	A1	Merck & Co., Inc.	05-11-2000	
W	62	WO	00/32574	A1	Sanofi-Synthelabo (abstract)	06-08-2000	
W	63	WO	00/39102	A1	Du Pont Pharmaceuticals Company	07-06-2000	
W	64	WO	00/69826	A1	Monsanto Company	11-23-2000	

Examiner Signature	V. Balasubramanian	Date Considered	11/29/04
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/680,723
				Filing Date	October 7, 2003
				Confirmation Number	2648
				First Named Inventor	Michael S. South, et al.
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	5	of	6	Attorney Docket No.	PHA 4159.33 (3203/1B/US)

WM	65	WO	00/69832	A1	Monsanto Company	11-23-2000	
WM	66	WO	00/69833	A1	Monsanto Company	11-23-2000	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
WM	67	COBURN, C.A., "Small-molecule direct thrombin inhibitors 1997-2000." Expert Opinions on Therapeutic Patents, 2001, 721-738, Vol. 11, No. 5	
WM	68	XP-002182132 - DARVAS, et al., "Investigation of the Common Mechanism of Action of Antibacterial Compounds Containing .gamma.-pyridone-.beta.-carboxylic acid Structure by Principal Component." Arzneim.-Forsch., 1979, pp. 1334-1339, Vol. 29, 9.	
WM	69	HANDIN, R., "Bleeding and Thrombosis." Harrison's Principles of Internal Medicine, 12th Edition, 1991, pp. 348-353, McGraw-Hill, Inc., New York.	
WM	70	XP-002172033 - KOHAMA et al., "Preparation of Piperidinyloxyacetylaminobenzoylalanine Derivatives and Analogs as Antithrombotics." JP 07,233,148.	
WM	71	MAJERUS, et al. "Anticoagulant, Thrombolytic, and Antiplatelet Drugs." Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, 1996, pp. 1341-1359, McGraw-Hill, New York.	
WM	72	XP-002187583 - MOERNER, Hoppe-Seyler's Z. Physiol. Chem., 69, 1910; 357.	
WM	73	PATEL et al., "Directed Aminomethylation of 3-Hydroxy-3(1H)-pyridinones and 3-hydroxy-4(1H)-pyridinones: Synthesis of Iso-Deferiprone." Tetrahedron, 1996, pp. 1835-1840, Vol. 52, No. 5.	
WM	74	SANDERSON, et al., "L-373,890, An Achiral, NonCovalent, Subnanomolar Thrombin Inhibitor." Bioorganic & Medical Chemistry Letters, 1997, pp. 1497-1500, Vol. 7, No. 12.	
WM	75	XP-002182410 - TRECOURT et al., "First Synthesis of (+)-harzianopyridone by Metalation of Polysubstituted O-pyridylcarbamates." J. Heterocycl. Chem., 1995, pp. 1117-1114, Vol. 32, No. 4.	


Examiner Signature	<i>M. Balasubramanian</i>	Date Considered	11/29/04
--------------------	---------------------------	-----------------	----------



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/680,723
				Filing Date	October 7, 2003
				Confirmation Number	2648
				First Named Inventor	Michael S. South, et al.
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	6	of	6	Attorney Docket No.	PHA 4159.33 (3203/1B/US)

	76	TULINSKY et al., "Novel Asymmetric Synthesis of Atropisomeric 6-Aryl Pyrazinones via an Unusual Chirality Transfer Process." J. Org. Chem., 1999, pp. 93-100, Vol. 64, No. 1.	

Examiner Signature		Date Considered	
--------------------	---	-----------------	---

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.